CATHERINE FERGUSON: Open Payments
NPI 1013520279 · HENDERSON, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$446 in 20 payments from 10 companies in 2025. Trend: 2023 $281 · 2024 $329 · 2025 $446
Food & beverage: $446
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 4 | $78 |
| PFIZER INC. | 3 | $76 |
| Astellas Pharma US Inc | 2 | $58 |
| Viatris Specialty LLC | 2 | $55 |
| GlaxoSmithKline, LLC. | 3 | $51 |
| Lilly USA, LLC | 2 | $40 |
| Esperion Therapeutics, Inc. | 1 | $25 |
| Seqirus USA Inc | 1 | $24 |
| Novo Nordisk Inc | 1 | $20 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $18 |
Products named: OTEZLA, PREVNAR 20, Veozah, YUPELRI, SHINGRIX, MOUNJARO, NEXLETOL, Fluad.
Industry payments across NV — which companies pay providers there.
